Categories
Change Password!
Reset Password!
Bromfenac is a sterile, topical nonsteroidal anti-inflammatory drug (NSAID) eye drop for ophthalmic use.
Bromfenac is a sterile, topical nonsteroidal anti-inflammatory drug (NSAID) eye drop for ophthalmic use. It is used for the management of ocular pain and inflammation because of its anti-inflammatory and analgesic properties. It blocks prostaglandin synthesis (a substance that causes inflammation (e.g., redness, swelling, irritation) by inhibiting cyclooxygenase 1 and 2.
Pharmacological class: NSAID
It works by its ability to block prostaglandin synthesis (a substance that causes inflammation (e.g., redness, swelling, irritation) by inhibiting cyclooxygenase 1 and 2. Prostaglandins are the mediators of certain kind of intraocular inflammation and they have shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
Cataract surgery: One drop twice daily, to be administered 24 hours’ post-surgery continuing through the first 2 weeks of the postoperative period.
The plasma concentration of bromfenac following ocular administration of bromfenac ophthalmic solution in humans is unknown. Based on the maximum proposed dose of one drop to the eye (0.09 mg) twice a day and pharmacokinetics information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.
Using bromfenac ophthalmic together with abciximab may cause dizziness, lightheadedness and also increases the risk of bleeding.
Common (affecting between 1 in 10 to 1 in 100):
Uncommon (affecting 1 in 100 to 1 in 1000):
Very rare (affecting less than 1 in 10,000):
Efficacy of bromfenac was evaluated in two randomized, double-masked, trials in which subjects with a summed ocular inflammation score ≥ 3 after cataract surgery were assigned to bromfenac or vehicle in a 2:1 ratio following surgery. One drop of bromfenac or vehicle was self-instilled in the study eye twice a day for 14 days, beginning the day after surgery. The primary endpoint was reduction of ocular inflammation (to trace inflammation or clearing) assessed 14 days’ post-surgery. Overall, only 20% of the patients undergoing cataract surgery in these trials had pain on the first day after surgery. In these patients, the bromfenac group demonstrated a statistically significant difference in median time to resolution of ocular pain of 2 days compared to 4 days for patients receiving vehicle.1
Comments (0)